Lugli Alessandro, Tzankov Alexandar, Zlobec Inti, Terracciano Luigi Maria
1Institute of Pathology, University Hospital of Basel, Basel, Switzerland.
Mod Pathol. 2008 Nov;21(11):1403-12. doi: 10.1038/modpathol.2008.117. Epub 2008 Jun 27.
The differentiation of colorectal cancer from primary tumors at other sites can be challenging. Often a panel of immunohistochemical protein markers is needed to distinguish between these entities. Protein expression differs significantly in colorectal cancer depending on mismatch repair status and is also heterogeneous among mismatch repair-proficient or -deficient tumors. The aim of this study was to systematically analyze the diagnostic and prognostic role of the commonly used multi-marker phenotype CK20/CK7/CDX2 on a large series of colorectal cancers stratified by mismatch repair status. The immunohistochemical analysis of CK20, CK7 and CDX2 was performed on 1197 mismatch repair-proficient and 223 mismatch repair-deficient colorectal cancers using a tissue microarray. Multi-marker combinations of CK20/CK7/CDX2 were explored. Univariate and multivariable analysis of the markers was evaluated for their association with several clinico-pathological end points namely T stage, N stage, tumor grade, vascular invasion, intratumoral lymphocytes and survival. Multi-marker phenotypes with CK20 and CDX2 negativity were more frequently found in mismatch repair-deficient than in mismatch repair-proficient colorectal cancer (19.3 vs 7.5% and 21.6 vs 6.7%, respectively; P<0.001). In both colorectal cancer subsets loss of CK20 was associated with higher tumor grade (P<0.001) and with presence of intratumoral lymphocytes (P<0.001 and P=0.02, respectively). In the proficient mismatch repair subset CK20 overexpression was an independent adverse prognostic factor (P=0.041) and CDX2 underexpression was linked to tumor progression. Loss of CDX2 and CK20 is more frequently encountered in mismatch repair-deficient colorectal cancer, which should be taken into consideration to differentiate between primary and metastatic colorectal cancer in daily practice. Although associated with lower tumor grade, CK20 overexpression is an independent adverse prognostic factor in mismatch repair-proficient colorectal cancer.
将结直肠癌与其他部位的原发性肿瘤区分开来可能具有挑战性。通常需要一组免疫组织化学蛋白标志物来区分这些实体。结直肠癌中的蛋白表达根据错配修复状态有显著差异,并且在错配修复 proficient 或 deficient 的肿瘤中也存在异质性。本研究的目的是系统分析常用的多标志物表型 CK20/CK7/CDX2 在一大系列按错配修复状态分层的结直肠癌中的诊断和预后作用。使用组织芯片对 1197 例错配修复 proficient 和 223 例错配修复 deficient 的结直肠癌进行了 CK20、CK7 和 CDX2 的免疫组织化学分析。探索了 CK20/CK7/CDX2 的多标志物组合。评估了这些标志物的单变量和多变量分析与几个临床病理终点(即 T 分期、N 分期、肿瘤分级、血管侵犯、肿瘤内淋巴细胞和生存)的关联。错配修复 deficient 的结直肠癌中 CK20 和 CDX2 阴性的多标志物表型比错配修复 proficient 的结直肠癌更常见(分别为 19.3%对 7.5%和 21.6%对 6.7%;P<0.001)。在两个结直肠癌亚组中,CK20 的缺失均与更高的肿瘤分级相关(P<0.001)以及与肿瘤内淋巴细胞的存在相关(分别为 P<0.001 和 P=0.02)。在错配修复 proficient 亚组中,CK20 过表达是一个独立的不良预后因素(P=0.041),而 CDX2 低表达与肿瘤进展相关。CDX2 和 CK20 的缺失在错配修复 deficient 的结直肠癌中更常出现,在日常实践中区分原发性和转移性结直肠癌时应予以考虑。尽管与较低的肿瘤分级相关,但 CK20 过表达在错配修复 proficient 的结直肠癌中是一个独立的不良预后因素。